Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

Researchers found that among semaglutide users, the incidence rate of nonarteritic anterior ischemic optic neuropathy ... other glucagon-like peptide 1 receptor agonists (GLP-1 RAs; dulaglutide ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

When James Norris, a 56-year-old mechanic from Roxbury, New Jersey, went on a low dose of Mounjaro, a GLP-1 medication ... arteritic anterior ischemic optic neuropathy (NAION), a condition in ...

Patients using popular weight loss medications, such as Ozempic and Wegovy, are being urged to undergo eye examinations due ...

Semaglutide was tied to nonarteritic anterior ischemic optic neuropathy (NAION ... an extra 2.5 to 76 added cases of NAION per 100,000 GLP-1 users per year. The statistically and clinically ...

WEDNESDAY, Feb. 26, 2025 (HealthDay News) — For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic anterior ischemic optic neuropathy ...

Increase in NAION associated with semaglutide use among individuals with type 2 diabetes. (HealthDay News) — For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly ...